<DOC>
	<DOC>NCT02028663</DOC>
	<brief_summary>The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Aged between 2070 Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified into LA Grade A to D within 14 days before randomization to treatment Patients who cannot undergo EGD Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected IBS Patients who took PPIs within 2 weeks prior to study drug administration Longterm use of nonsteroidal antiinï¬‚ammatory drugs throughout the study Clinically significant abnormal laboratory values during screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>P-CAB</keyword>
	<keyword>APA(Acid Pump Antagonist)</keyword>
</DOC>